[go: up one dir, main page]

MA31264B1 - Methodes de traitement du cancer comprenant l'administration de l'il-18 humaine en combinaison - Google Patents

Methodes de traitement du cancer comprenant l'administration de l'il-18 humaine en combinaison

Info

Publication number
MA31264B1
MA31264B1 MA32234A MA32234A MA31264B1 MA 31264 B1 MA31264 B1 MA 31264B1 MA 32234 A MA32234 A MA 32234A MA 32234 A MA32234 A MA 32234A MA 31264 B1 MA31264 B1 MA 31264B1
Authority
MA
Morocco
Prior art keywords
combination
human
methods
treating cancer
administering human
Prior art date
Application number
MA32234A
Other languages
Arabic (ar)
English (en)
Inventor
Zdenka Haskova
Zdenka Ludmila Jonak
Stephen H Trulli
Margaret N Whitacre
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39788932&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31264(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of MA31264B1 publication Critical patent/MA31264B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne d'une manière générale l'utilisation de l'il-18 humaine en combinaison dans le traitement de diverses formes de tumeurs solides et de lymphomes. Cette invention concerne en particulier (1) l'utilisation de l'il-18 humaine combinée à des anticorps monoclonaux dirigés contre des antigènes exprimés sur la surface de cellules cancéreuses; et (2) l'utilisation de l'il-18 humaine combinée à des agents chimiothérapeutiques.
MA32234A 2007-03-23 2009-09-24 Methodes de traitement du cancer comprenant l'administration de l'il-18 humaine en combinaison MA31264B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89685507P 2007-03-23 2007-03-23
US95200207P 2007-07-26 2007-07-26
PCT/US2008/057615 WO2008118733A2 (fr) 2007-03-23 2008-03-20 Méthodes de traitement du cancer comprenant l'administration de l'il-18 humaine en combinaison

Publications (1)

Publication Number Publication Date
MA31264B1 true MA31264B1 (fr) 2010-03-01

Family

ID=39788932

Family Applications (2)

Application Number Title Priority Date Filing Date
MA32235A MA31265B1 (fr) 2007-03-23 2009-09-24 Traitement du cancer au moyen de l'il-18 humaine combinee a un anticorps anti-cd20
MA32234A MA31264B1 (fr) 2007-03-23 2009-09-24 Methodes de traitement du cancer comprenant l'administration de l'il-18 humaine en combinaison

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA32235A MA31265B1 (fr) 2007-03-23 2009-09-24 Traitement du cancer au moyen de l'il-18 humaine combinee a un anticorps anti-cd20

Country Status (21)

Country Link
US (4) US20090035258A1 (fr)
EP (3) EP2129398A4 (fr)
JP (2) JP2010522200A (fr)
KR (2) KR20100015798A (fr)
CN (1) CN101678102A (fr)
AR (2) AR065803A1 (fr)
AU (2) AU2008231025A1 (fr)
BR (2) BRPI0809079A2 (fr)
CA (2) CA2681827A1 (fr)
CL (2) CL2008000818A1 (fr)
CR (2) CR10996A (fr)
DO (2) DOP2009000208A (fr)
EA (2) EA200970885A1 (fr)
IL (2) IL200525A0 (fr)
MA (2) MA31265B1 (fr)
MX (2) MX2009010269A (fr)
NZ (1) NZ579179A (fr)
PE (2) PE20090190A1 (fr)
SG (1) SG171674A1 (fr)
TW (2) TW200906436A (fr)
WO (2) WO2008118736A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102206277A (zh) * 2000-02-10 2011-10-05 雅培制药有限公司 结合人白介素-18的抗体及制备和使用方法
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
PE20090190A1 (es) * 2007-03-23 2009-03-22 Smithkline Beecham Corp Combinacion de anticuerpos anti-cd20 y polipeptidos de il-18
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
LT3134124T (lt) 2014-04-25 2019-05-27 Pierre Fabre Médicament Igf-1r antikūno ir vaisto konjugatas, ir jo panaudojimas vėžio gydymui
PT3134125T (pt) 2014-04-25 2020-01-13 Pf Medicament Conjugado-fármaco-anticorpo e sua utilização para o tratamento de cancro
CA2957387A1 (fr) * 2014-08-07 2016-02-11 Hyogo College Of Medicine Agent therapeutique contre le cancer contenant une combinaison d'il-18 et d'anticorps de ciblage de molecules
WO2016126615A1 (fr) * 2015-02-03 2016-08-11 Armo Biosciences, Inc. Procédés d'utilisation de l'interleukine-10 pour le traitement de maladies et de troubles
US20240368247A1 (en) * 2020-12-02 2024-11-07 The Royal Institution For The Advancement Of Learning/Mcgill University Therapeutic applications of type 1 insulin-like growth factor (igf-1) receptor antagonists
WO2025033330A1 (fr) * 2023-08-04 2025-02-13 医療革新国際連携株式会社 Thérapie antitumorale par utilisation combinée d'un inhibiteur de chymase et d'une immunothérapie

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69519454T2 (de) 1994-07-14 2001-05-03 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo, Okayama Protein, das Interferon-Gamma Herstellung induziert und monoklonaler Antikörper dagegen
TW581771B (en) 1994-11-15 2004-04-01 Hayashibara Biochem Lab Recombinant production of a polypeptide for inducing interferon-gamma production, and monoclonal antibody against the polypeptide
JP4004088B2 (ja) 1995-09-26 2007-11-07 株式会社林原生物化学研究所 免疫担当細胞においてインターフェロン−γの産生を誘導する蛋白質
US7135458B1 (en) * 1995-11-15 2006-11-14 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interferon-γ inducing polypeptide, pharmaceutical composition thereof, monoclonal antibody thereto, and methods of use
US5680795A (en) 1995-07-05 1997-10-28 Norco Inc. Mechanical drive assembly incorporating counter-spring biassed radially-adjustable rollers
JP4024366B2 (ja) * 1996-11-29 2007-12-19 株式会社林原生物化学研究所 ポリペプチド
US6787132B1 (en) * 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
TWI227136B (en) * 1998-05-21 2005-02-01 Smithkline Beecham Corp Novel pharmaceutical composition for the prevention and/or treatment of cancer
PL208592B1 (pl) * 2000-06-15 2011-05-31 Smithkline Beecham Corp Sposób wytwarzania aktywnego ludzkiego polipeptydu IL-18 z ludzkiego polipeptydu prekursora IL-18
US20020094323A1 (en) * 2000-10-12 2002-07-18 Kristoffer Hellstrand Methods and compositions for promoting the maturation of monocytes
CN101914158A (zh) * 2002-02-14 2010-12-15 免疫医疗公司 抗cd 20抗体及其融合蛋白和使用方法
US20040001828A1 (en) * 2002-02-21 2004-01-01 Joseph Tuscano Treatment methods using anti-CD22 antibodies
ATE497778T1 (de) * 2002-09-16 2011-02-15 Agennix Inc Lactoferrin-zusammensetzungen und verfahren zur behandlung von diabetischen ulcus
WO2004032962A1 (fr) * 2002-10-08 2004-04-22 Immunomedics, Inc. Therapie associant des anticorps monoclonaux anti-ace de classe iii a des agents therapeutiques
SI1558648T1 (sl) * 2002-10-17 2012-05-31 Genmab As Človeška monoklonalna protitelesa proti CD
US7534427B2 (en) * 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
WO2004091517A2 (fr) * 2003-04-15 2004-10-28 Smithkline Beecham Corporation Conjugues comprenant l'interleukine 18 humaine il 18 et mutants de ces conjugues par substitution
US20050075277A1 (en) * 2003-07-10 2005-04-07 Agennix Incorporated Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects
US7109304B2 (en) * 2003-07-31 2006-09-19 Immunomedics, Inc. Humanized anti-CD19 antibodies
RU2412199C2 (ru) * 2005-04-18 2011-02-20 Ново Нордиск А/С Варианты ил-21
KR20080030673A (ko) * 2005-07-21 2008-04-04 젠맵 에이/에스 Ｆｃ 수용체와 결합하는 항체 약품 성분에 대한 효력 검정
WO2008008981A1 (fr) * 2006-07-13 2008-01-17 Zymogenetics, Inc. Traitement de combinaison d'interleukine 21 et d'inhibiteur de tyrosine kinase
CA2662609A1 (fr) * 2006-09-14 2008-03-20 The Trustees Of The University Of Pennsylvania Modulation de lymphocytes t regulateurs par l'il-18 humaine
PE20090190A1 (es) * 2007-03-23 2009-03-22 Smithkline Beecham Corp Combinacion de anticuerpos anti-cd20 y polipeptidos de il-18

Also Published As

Publication number Publication date
AR065803A1 (es) 2009-07-01
KR20100015798A (ko) 2010-02-12
SG171674A1 (en) 2011-06-29
AU2008231114A1 (en) 2008-10-02
CL2008000818A1 (es) 2008-09-26
EP2129398A4 (fr) 2010-04-21
CR11075A (es) 2010-03-22
IL200863A0 (en) 2010-05-17
AR065818A1 (es) 2009-07-01
DOP2009000208A (es) 2010-03-31
EP2136841A4 (fr) 2010-07-07
KR20100014530A (ko) 2010-02-10
AU2008231025A1 (en) 2008-10-02
TW200904469A (en) 2009-02-01
NZ579179A (en) 2011-12-22
MX2009010271A (es) 2009-10-12
CR10996A (es) 2009-11-12
WO2008118733A3 (fr) 2008-11-27
CA2681827A1 (fr) 2008-10-02
US20100196310A1 (en) 2010-08-05
BRPI0809079A2 (pt) 2019-03-06
CL2008000842A1 (es) 2008-10-17
PE20090184A1 (es) 2009-03-22
BRPI0808943A2 (pt) 2014-08-26
WO2008118733A2 (fr) 2008-10-02
EP2129398A1 (fr) 2009-12-09
JP2010522239A (ja) 2010-07-01
WO2008118736A1 (fr) 2008-10-02
MA31265B1 (fr) 2010-03-01
DOP2009000220A (es) 2009-10-31
EP2338514A1 (fr) 2011-06-29
IL200525A0 (en) 2010-04-29
JP2010522200A (ja) 2010-07-01
EA200970885A1 (ru) 2010-02-26
EA200970884A1 (ru) 2010-04-30
CN101678102A (zh) 2010-03-24
US20090035258A1 (en) 2009-02-05
TW200906436A (en) 2009-02-16
PE20090190A1 (es) 2009-03-22
EP2136841A2 (fr) 2009-12-30
CA2681851A1 (fr) 2008-10-02
US20080274078A1 (en) 2008-11-06
MX2009010269A (es) 2009-10-12
US20100111945A1 (en) 2010-05-06

Similar Documents

Publication Publication Date Title
MA31264B1 (fr) Methodes de traitement du cancer comprenant l'administration de l'il-18 humaine en combinaison
EA201300246A1 (ru) Ингибиторы тирозинкиназы брутона
MA31862B1 (fr) Anticorps anti-mésothéline et leurs utilisations
MA31205B1 (fr) Combinaisons d'agents therapeutiques pour le traitement du cancer
TW200612918A (en) Lonidamine analogs
MA39094A1 (fr) Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
UA105760C2 (uk) Антитіло проти bst2
MA33839B1 (fr) Compositions et procédés destinés à diagnostiquer et à traiter des tumeurs
TW200630105A (en) Herbal composition PHY906 and its use in chemotherapy
EA200600468A1 (ru) Биполярные транс-каротиноидные соли и их применение
MA29587B1 (fr) Compositions et methodes de diagnostic et de traitement de tumeur
WO2007065124A3 (fr) Methodes d'identification et de traitement d'individus presentant des karyotypes complexes